KROS

Business Context and Reporting Period

Company: Keros Therapeutics, Inc. (KROS)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Keros is a clinical-stage biopharmaceutical company developing therapeutics targeting the TGF-β family of proteins. Its pipeline includes three primary candidates: cibotercept (KER-012) for pulmonary arterial hypertension (PAH); KER-065 for neuromuscular diseases; and elritercept (KER-050) for cytopenias in myelodysplastic syndromes (MDS) and myelofibrosis.

Key Financial Metrics

Liquidity: As of December 31, 2024, the company held $559.9 million in cash and cash equivalents. Management projects this balance, combined with a $200.0 million upfront payment received from Takeda in February 2025, will fund operations into 2029.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased to $3.6 million in 2024 from $0.2 million in 2023. This was driven by $3.0 million in license revenue from a development milestone achieved under the Hansoh agreement and $0.6 million in service revenue.
• Expense Increases: Net loss widened by approximately $34.4 million year-over-year. R&D expenses rose $38.4 million, primarily due to increased clinical spend for cibotercept (Phase 2), KER-065 (Phase 1), and elritercept (Phase 2 and Phase 3 initiation), alongside higher personnel and stock-based compensation costs.
• Capital Raising: The company raised significant capital in 2024, including $151.1 million from a January public offering and $228.6 million from "at-the-market" (ATM) sales.

Guidance, Outlook, and Material Events

Strategic Collaboration

In December 2024, Keros entered into an exclusive license agreement with Takeda Pharmaceuticals for the global development and commercialization of elritercept (excluding mainland China, Hong Kong, and Macau). The agreement became effective January 16, 2025. Keros received a $200.0 million upfront payment in February 2025, with potential for up to $1.11 billion in additional milestone and royalty payments.

Clinical Trial Updates

• Cibotercept (KER-012): The Phase 2 TROPOS trial in PAH was terminated early in January 2025 following a safety review due to unanticipated pericardial effusion adverse events. Topline data is expected in Q2 2025.
• Elritercept (KER-050): The company initiated a Phase 3 trial (RENEW) in lower-risk MDS in December 2024. Additional Phase 2 data for MDS and myelofibrosis were presented in December 2024, showing durable transfusion independence in subsets of patients.
• KER-065: A Phase 1 trial in healthy volunteers is ongoing, with initial data expected in Q1 2025.

Risks and Contingencies

The early termination of the cibotercept trial represents a significant clinical risk. The company must evaluate future development strategies for this asset. Additionally, the company remains dependent on the success of its collaborations with Takeda and Hansoh for future revenue streams and has no approved products for commercial sale.

Investor Verification Checklist

• Takeda Agreement Terms: Verify the specific development milestones and royalty tiers in the Takeda agreement to understand future revenue potential.
• Cibotercept Safety Review: Monitor the Q2 2025 topline data release for the TROPOS trial to assess the severity of the pericardial effusion events and the viability of the asset.
• Elritercept Phase 3 Design: Review the enrollment progress and primary endpoint design of the RENEW Phase 3 trial in MDS.
• Cash Runway: Confirm the burn rate against the projected 2029 liquidity horizon, considering the impact of the Takeda upfront payment.
• Intellectual Property: Review the patent portfolio expiration dates for elritercept and cibotercept to assess long-term exclusivity.